Allcutis Research, LLC — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$20,420	42
2024	Research	$210,368	45
2023	Research	$16,633	4
2022	Research	$724	1
2021	Research	$1,000	1

Breakdown

Who paid Research payments · program years 2021–2025

Incyte Corporation $215,292 85 payments
E.R. Squibb & Sons, L.L.C. $32,038 5 payments
AstraZeneca UK Limited $1,000 1 payment
Verrica Pharmaceuticals Inc. $815 2 payments

Studies the money was for Research payments · program years 2021–2025

A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo $194,871 43 payments
Phase 2b POC PsO Study - A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986322 in Participants with Moderate-to-Severe Psoriasis $29,873 2 payments
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo $19,075 3 payments
A Multicenter, Randomized, Placebo-Controlled Study Evaluting the Efficacy and Safety of Deucravacitinib in Patients With Moderate to Severe Scalp Psoriasis $2,165 3 payments
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa $1,345 39 payments
A Phase 2b, Randomised, Double-Blind, Placebo-Controlled, Multi Centre Study to Evaluate the Efficacy, Safety and Tolerability of Oral AZD9977 and Dapagliflozin Treatment in Patients with Heart Failure with Left Ventricular Ejection Fraction (LVEF) Below 55 percent and Chronic Kidney Disease $1,000 1 payment
A Phase 2, Multicenter, Open Label, Proof of Concept Study With Safety Run-In to Evaluate the Safety, Pharmacokinetics, and Efficacy of Vp-315 in Adult Subjects With Basal Cell Carcinoma $815 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.